Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Sep 14, 2020

Mustang Bio to Participate in Three September 2020 Virtual Investor Conferences

Sep 10, 2020

Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences

Sep 10, 2020

Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences

Sep 10, 2020

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

Sep 09, 2020

Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Sep 02, 2020

Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Aug 31, 2020

Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

Aug 28, 2020

Fortress Biotech Announces $60 Million Loan Agreement with Oaktree Capital Management

Aug 28, 2020

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

Aug 26, 2020
RSS
  • Prev
    • 1...
    • 37
    • 38
    • 39
    • 40
    • 41
    • 42
    • 43
    • 44
    • 45
    • 46
    • ...71
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap